Dermata Therapeutics   Report issue

For profit Phase 2 Phase 3
Founded: Encinitas CXA United States (2014)

Organization Overview

First Clinical Trial
2016
NCT02949960
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Dermata Therapeutics

Active Ingredients

Drugs in Phase 3 Trials (1)

dmt310 (3 trials)

Drugs in Phase 2 Trials (2)

dmt210 (2 trials)

hydrogen peroxide (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acne Vulgaris (Phase 2)

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Rosacea (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 3